INMB INmune Bio Inc.
$2.22▼ -3.90%
Healthcare
Other
After hours
$2.22▲ +0.00%
Sep 11, 7:30 PM ET
Volume 228.1K
Avg Volume (10D) 279.4K
Key Metrics & Fundamentals
Market Cap
$61.61M
P/E Ratio
–
Div Yield
–%
52W Range
1.09 - 2.60
% vs 50 MA
8.37%
% vs 200 MA
37.19%
RSI-14
49.8
MACD Histogram
-0.0200
Beta (1Y vs SPY)
2.45
Free Cash Flow
-$3.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.41M
COGS
–
Operating Exp
$1.48M
Operating Income
-$1.48M
EBIT
-$1.48M
Pretax Income
-$1.27M
Net Income
-$1.27M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
GlobeNewswire · Sep 9, 2026 12:00 PM
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
GlobeNewswire · Aug 26, 2026 11:00 AM
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 7, 2026 6:11 AM
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
GuruFocus.com · Aug 7, 2026 5:08 AM
INmune Bio, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 4:37 AM
INmune Bio Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 3:03 AM
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
GlobeNewswire · Aug 6, 2026 8:00 PM
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
GlobeNewswire · Jul 31, 2026 11:00 AM
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
GlobeNewswire · Jul 31, 2026 11:00 AM
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
GlobeNewswire · Jul 30, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
Mar 2025
See INMB's money flow as a full page
Social Sentiment
Avg +0.60 · 2 posts
TradeDiscussionSkreli is the goat? Yes or no
r/investing · Jun 30, 2025
Inmune Bio was presented as a stock recommendation, indicating a positive sentiment.
positive
+0.60
NewsDiscussionDD[INMB] INmune Bio Inc. - High risk/high reward
r/investing · Jun 2, 2025
The post discusses a Phase II clinical trial, expected topline results, and positive pilot study results, indicating optimism.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.